Long-Term Patient Care Focuses on Precision-Based Therapy in Breast Cancer

Dr. Maxwell Lloyd, a Clinical Fellow in Medicine in the Department of Medicine at Beth Israel Deaconess Medical Center in Boston, sat down for in interview with CURE® at the 2024 San Antonio Breast Cancer Symposium. In the interview, he shared insights on the long-term management of patients with HR-positive, HER2-negative breast cancer who have received Orserdu (elacestrant) treatment

“It's an evolving area, with various treatment paradigms that are available,” Lloyd emphasized, highlighting that, as time goes on, clinicians are aiming to incorporate more precision-based therapeutic options into treatment strategies.

To hear more of Lloyd’s insights, read his full response here.

Transcript:

Post-Orserdu, there are still a number of treatment options for patients with advanced breast cancer that's going to be personalized and patient dependent. [These treatments] continue to focus on potential strategies of precision-based therapies in order to find the right treatment for the right patient at the right time. In regard to the post-Orserdu landscape — in terms of genomic sequencing — we still don't have a robust understanding of what that might look like in the way that we do after first-line endocrine therapy and CDK4/6 inhibitor. There may be similar targets for a targeted therapeutic or combination strategy that can help us delay the initiation of a more standard chemotherapy.

Some patients may have breast cancer that is more rapidly progressive, less endocrine therapy sensitive. Those are the folks that we [may consider] something like Enhertu [trastuzumab deruxtecan; T-DXd] if it's HER2-low or ultra-low, or a more traditional line of chemotherapy like capitaine. It's an evolving area, with various treatment paradigms that are available.

We need to look at these clinical and genomic factors to help predict what patients are going to benefit most and minimize any unnecessary toxicity by avoiding giving treatments to patients that may not [respond well to treatment]. This is part of an ongoing effort [which continues to] tailor therapy to the underlying biology of the patient's tumor with the hope to help people live longer, healthier, more full lives.

Transcript was edited for clarity and conciseness.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.